Blood Tests for Alzheimer’s and Dementia: New Breakthroughs in Early Detection
For decades, diagnosing Alzheimer’s disease required expensive brain scans or invasive procedures such as spinal taps. Today, a new generation of blood tests for Alzheimer’s disease is transforming how doctors detect and monitor dementia.
These blood tests measure specific proteins associated with brain changes that occur in Alzheimer’s disease and other neurodegenerative disorders. In many cases, they can detect these changes years before symptoms appear.
Researchers believe these tests may significantly improve early diagnosis, help doctors choose treatments, and make it easier for patients to participate in clinical trials.
Why Early Detection of Alzheimer’s Matters
Alzheimer’s disease begins developing in the brain many years before noticeable memory problems occur. During this early phase, abnormal proteins accumulate and damage brain cells.
Early detection allows doctors and families to:
- Identify cognitive decline sooner
- Access new Alzheimer’s medications earlier
- Plan for future care
- Participate in clinical trials
- Rule out other causes of memory loss
Blood tests are making this early detection more accessible.
How Blood Tests Detect Alzheimer’s Disease
Blood tests for Alzheimer’s measure proteins released into the bloodstream when brain cells are damaged or when abnormal proteins accumulate in the brain.
The most important biomarkers include:
- Amyloid beta proteins
- Tau proteins
- Neurofilament light chain
- Inflammatory markers
These proteins reflect biological processes occurring in the brain long before symptoms appear.
Key Biomarkers Used in Alzheimer’s Blood Tests
Amyloid Beta (Aβ42 and Aβ40)
Amyloid proteins form plaques in the brains of people with Alzheimer’s disease. Blood tests often measure the ratio between two amyloid proteins:
- Aβ42
- Aβ40
Lower Aβ42/Aβ40 ratios are associated with amyloid plaque accumulation in the brain.
These measurements correlate closely with amyloid PET brain scans.
Phosphorylated Tau (p-tau)
Tau proteins help stabilize neurons. In Alzheimer’s disease, abnormal tau accumulates inside brain cells and forms tangles.
Blood tests commonly measure several tau variants:
- p-tau181
- p-tau217
- p-tau231
Among these, p-tau217 has emerged as one of the most accurate blood markers for Alzheimer’s disease.
Neurofilament Light Chain (NfL)
Neurofilament light chain is released when nerve cells are damaged.
Elevated NfL levels can indicate neurodegeneration, although the marker is not specific to Alzheimer’s disease and may also appear in conditions such as:
- Frontotemporal dementia
- Multiple sclerosis
- Traumatic brain injury
Glial Fibrillary Acidic Protein (GFAP)
GFAP reflects activation of astrocytes, support cells in the brain that respond to injury and inflammation.
Elevated GFAP levels may signal early Alzheimer’s pathology.
Major Blood Tests Currently Available
Several companies and research groups have developed blood tests designed to detect Alzheimer’s biomarkers.
| Test | Developer | Purpose |
|---|---|---|
| PrecivityAD | C2N Diagnostics | Measures amyloid biomarkers and APOE genotype |
| PrecivityAD2 | C2N Diagnostics | Advanced test measuring p-tau217 |
| Quest AD-Detect | Quest Diagnostics | Measures amyloid beta ratios |
| Labcorp ATN Profile | Labcorp | Measures amyloid and tau biomarkers |
These tests are increasingly being used in memory clinics and research settings.
Accuracy of Alzheimer’s Blood Tests
Recent studies show that some blood tests can identify Alzheimer’s pathology with 80–90% accuracy when compared with amyloid PET scans.
Research from institutions such as the Mayo Clinic, Washington University, and Lund University suggests that biomarkers like p-tau217 may rival more expensive diagnostic methods.
However, doctors typically combine blood test results with:
- Cognitive assessments
- Medical history
- Neurological exams
- Brain imaging
Who Should Consider Alzheimer’s Blood Testing
Doctors may recommend these tests when a person experiences symptoms such as:
- Persistent memory loss
- Difficulty planning or organizing tasks
- Confusion about time or place
- Language difficulties
- Changes in judgment
Blood tests may also be used to evaluate individuals with mild cognitive impairment (MCI).
Limitations of Blood Tests
Although promising, blood tests are still evolving.
Limitations include:
- Some biomarkers appear in multiple neurological conditions
- Results must be interpreted alongside clinical evaluations
- Not all healthcare providers currently offer these tests
For these reasons, blood tests are typically used as part of a broader diagnostic process.
How to Get Tested
Blood tests for Alzheimer’s can be ordered through:
- Neurologists
- Memory clinics
- Academic medical centers
Some laboratory providers also allow physicians to order tests through specialized diagnostic panels.
Patients interested in testing should consult a physician who specializes in cognitive disorders.
Research and Future Developments
Scientists continue to refine blood biomarkers for dementia. Researchers are investigating additional markers that may improve early detection and help distinguish between different types of dementia.
Future tests may be able to identify Alzheimer’s disease decades before symptoms appear and help guide personalized treatment strategies.
Organizations and Resources
- Alzheimer's Association — https://www.alz.org
- National Institute on Aging — https://www.nia.nih.gov
- Alzheimer’s Disease Research Centers — https://www.nia.nih.gov/health/alzheimers-disease-research-centers
- Clinical Trials Finder — https://clinicaltrials.gov
Why These Tests Are Transforming Dementia Care
Blood tests represent one of the most important advances in dementia research in decades. By making early detection easier and more affordable, they may allow millions of people to receive diagnosis and treatment sooner.
As research progresses, blood biomarkers may play a central role in screening, diagnosis, and monitoring of Alzheimer’s disease and other neurodegenerative conditions.